Thematic Exposure -- 8/10
Theme: DNA / next-generation sequencing (NGS) — the picks-and-shovels layer of genomics. Illumina
sells the sequencers and, more importantly, the proprietary consumables (flow cells, reagents) that
run on them. Post-GRAIL spin (2024), this is a pure-play "Core Illumina" franchise: a
razor/razor-blade model where instruments seed a locked-in recurring consumables stream (~66% of
revenue) where the moat lives. Near-monopoly (~66-80% of NGS installed base, >90% of clinical
genomics) in a structurally growing theme (~14-18% NGS CAGR). The oligopoly hard gate is comfortably
cleared; the 8/10 sits at the top of the 7-8 band.
Weight: 35%
DNA / NGS -- Structurally Growing Theme
Secular Tailwind -- Multi-Year Visibility
NGS is a ~$12-17B market (2026) growing ~14-18% CAGR, with clinical genomics the durable,
reimbursement-driven core (+20% ex-China). Output on connected instruments grew >30% YoY, so
the consumable pull-through is structural. Illumina is the reference platform across research,
clinical, and applied/population-genomics programs.
Near-Monopoly -- The Dominant Oligopolist
Oligopoly Gate: PASS
Illumina holds ~66-80% of the global NGS installed base and >90% of clinical genomics testing
— well above the 30% dominant-share bar and the single dominant player. The closest scaled peer
(Thermo Fisher Ion Torrent) is well under 15%; Element, Ultima, MGI, ONT, and PacBio are each
low-single-digit. This is a near-monopoly with a long fringe, not a fragmented market.
Razor/Blade Consumables Annuity
Recurring Revenue -- Multi-Year Switching Costs
~80% of revenue is recurring consumables + service. Clinical customers run FDA-cleared assays
locked to Illumina chemistry; revalidating a regulated assay on a rival platform takes years.
76% of clinical and 90% of research volume now sits on NovaSeq X — switching means re-buying
instruments AND re-validating workflows. Illumina is a clear price-maker, running an "elasticity
game" on price-per-gigabase.
Segment Mix (Q1 2026 Revenue)
| Segment |
% of Revenue |
Market Share |
Theme Growth |
| Sequencing Consumables |
~66.5% |
>90% clinical; ~66-80% installed base |
~14-18% CAGR (clinical +20% ex-China) |
| Sequencing Service & Other |
~13.8% |
Tied to installed base (dominant) |
+7% YoY; lumpy |
| Sequencing Instruments |
~10.8% |
~66% of global system installations |
+9% YoY; supply-constrained |
| Microarrays / Other |
~8.7% |
Legacy (Illumina/Thermo duopoly) |
-20% organic (DTC weakness) |
| Total |
100% |
— |
+4.8% reported / +1.2% organic |
Key competitors: Element Biosciences, Ultima Genomics, MGI/Complete Genomics, Oxford Nanopore, PacBio, Thermo Fisher, and Roche (SBX, clinical launch pending). Most are sub-scale niche/cost players today; Illumina remains the reference platform.
Oligopoly Gate
| Criterion |
Result |
| Illumina share in NGS installed base |
~66-80% |
| Share of clinical genomics testing |
>90% |
| Any competitor >15% share? |
No — near-monopoly |
| Price-maker or price-taker? |
Price-maker (sets price) |
| Gate result |
PASS |
Three Gating Questions
1. Competitors with >15% share in each segment?
In NGS, zero. Illumina holds ~66-80% of the installed base and >90% of clinical genomics testing;
the closest scaled peer (Thermo Ion Torrent) is well under 15%. The market is NOT fragmented — a
near-monopoly with a long fringe.
2. Could a customer replace Illumina within 12 months?
No. Clinical customers run FDA-cleared/validated assays locked to Illumina chemistry; revalidating a
regulated assay takes years. 76% of clinical and 90% of research volume sits on NovaSeq X — switching
means re-buying instruments AND re-validating workflows.
3. Does Illumina set or take prices?
Sets — the price-maker. It runs an "elasticity game," cutting price-per-gigabase to drive volume on
its own terms; it raised FY26 guidance the same quarter a rival launched a $150-genome platform.
8/10 — Textbook "leaders in a market
remain leaders": a near-monopoly (~66-80% of NGS, >90% of clinical genomics) in a structurally
growing theme (~14-18% NGS CAGR), with a razor/blade consumables annuity and multi-year switching
costs that make it a clear price-maker. The oligopoly hard gate is comfortably cleared. It misses a
perfect 10 only because (a) company-level growth is high-single-digit, not theme-level mid-teens
(China structural decline, research/applied falling double-digits on NIH uncertainty, organic
+1.2%); and (b) competitors are finally arming up (Element, Ultima's $100 genome, Roche clinical
SBX). Solidly top of the 7-8 band.